Simone N. Koole
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 21, 2026
Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer.
Journal: JCO oncology practice
Published: December 19, 2025
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.
Journal: Nature communications
Published: October 22, 2024
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.
Journal: Cancer cell
Published: March 05, 2024
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Journal: British journal of cancer
Published: December 19, 2023
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications.
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications.
Journal: The Lancet. Oncology
Published: September 18, 2023
Differences in time to patient access to innovative cancer medicines in six European countries.
Journal: International journal of cancer
Published: July 14, 2023
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: May 04, 2023
Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Journal: International journal of cancer
Published: June 26, 2022
Last Updated: 09/26/2026